Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group

Trial Profile

Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary) ; Desloratadine (Primary) ; Mometasone (Primary) ; Olopatadine (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Conjunctivitis
  • Focus Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 14 Sep 2017 Primary endpoint has been met. (Combined rhinoconjunctivitis symptom and deciation score.), as reported in an ALK Abello Media Release
    • 14 Sep 2017 Results published in the ALK Abello Media Release
    • 11 Aug 2017 The trial has been completed in Denmark (On-2017-06-20) according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top